Antidepressant-induced suicidality: How translational epidemiology incorporating pharmacogenetics into controlled trials can improve clinical care

Personalized Medicine

Volumn 11, Issue 1, 2014, Pages 79-88

  Healy, David ^a   Bechthold, Kim ^b   Tolias, Peter ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Sundance DX Inc   (United States)

^c Stevens Institute of Technology   (United States)

Author keywords

antidepressants; drug response; pharmacogenetics; randomized controlled trials; suicidal ideation; translational epidemiology

Indexed keywords

EID: 84893869830     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.93     Document Type: Review

References (38)

1. Fisher RA. The Design of Experiments (9th Edition). Macmillan, London, UK (1935).
2. Savage LJ. On rereading RA Fisher. Ann. Statistics 4, 441-500 (1976).
3. Marks HM. The Progress of Experiment. Cambridge University Press, Cambridge, UK (2000).
4. Healy D. The antidepressant tale: figures signifying nothing? Adv. Psychiatr. Treat. 12, 320-328 (2006).
5. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2(4582), 769-782 (1948).
6. Toth B. Clinical trials in British medicine 1858-1948, with special reference to the development of the randomised controlled trial. Dissertation, University of Bristol, Bristol, UK (1998).
7. Hill AB. Reflections on the controlled trial. Ann. Rheum. Dis. 25, 107-133 (1966).
8. The Empire of Chance. Gigerenzer G (Ed.). Cambridge University Press, Cambridge, UK (1990).
9. Healy D. Pharmageddon. University of California Press, CA, USA (2012).
10. Lasagna L. Thalidomide-a new non-barbiturate sleep-inducing drug. J. Chronic Dis. 11, 627-631 (1960).
11. Hohn R, Gross GM, Gross M, Lasagna L. A double-blind comparison of placebo and imipramine in the treatment of depressed patients in a state hospital. J. Psychiatr. Res.1, 76-91 (1961).
12. Raffle A, Gray M. Screening: Evidence and Practice. Oxford University Press, Oxford, UK (2007).
13. Pratt LA, Brody DJ, Gu Q. Antidepressant Use in Persons Aged 12 and Over: United States, 2005-2008. NCHS Data Brief, No 76. National Center for Health Statistics, MD, USA (2011).
14. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am. J. Psychiatry 157, 1925-1932 (2002).
15. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593-602 (2005). (Pubitemid 40973434)
16. Perlis RH, Beasley CM , Wines JD Jr et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother. Psychosom. 76, 40-46 (2007). (Pubitemid 46005718)
17. Seemuller F, Riedel M, Obermeier M ,The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int. J. Neuropsychopharmacol. 12, 181-189 (2009).
18. Davies EB. Proceedings of the Symposium held at Cambridge, 22-26 September 1959. Clark D et al. 86-89 Cambridge University Press, Cambridge, UK (1962).
19. Healy D. The Antidepressant Era. Harvard University Press, MA, USA (1998).
20. Hagnell O, Lanke J, Rorsmart B. Suicide rates in the Lundby study: mental illness as a risk factor for suicide. Neuropsychobiology 7, 248-253 (1981). (Pubitemid 11053459)
21. Stone M, Jones L. Clinical review: relationship between antidepressant drugs and adult suicidality. US FDA, Washington, DC, USA (2006).www.fda.gov/ ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
22. Teicher MH, Glod C, Cole JO. Suicidal preoccupation during fluoxetine treatment. Am. J. Psychiatry 147, 1380-1381 (1990).
23. Greenland S, Robins JM. Identifiability, exchangeability, and epidemiological confounding. Int. J. Epidemiol. 15, 412-418 (1988).
24. Lanes SF. Biological interpretation of relative risk. Drug Safety 21, 75-79 (1999). (Pubitemid 29389168)
25. Rothman KJ, Greenland S, Lash T. Modern Epidemiology. Lippincott, Williams & Wilkins, PA, USA (2008).
26. Montgomery DB, Roberts A, Green M, Bullock T, Baldwin D, Montgomery SA. Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. Eur. Arch. Psych. Clin. Neurosci. 244, 211-215 (1994). (Pubitemid 24361645)
27. der Mast RC Van, Hengeveld MW, Tuyl JP, Zwindermann AH, Van Kempen GM. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am. J. Psychiatry 155, 543-547 (1998). (Pubitemid 28207452)
28. G. S. Kline. Paroxetine adult suicidality analysis. GlaxoSmithKline (2006).www.gsk.com/media/paroxetine/briefing-doc.pdf
29. Laje G, Paddock S, Manji H. Genetic markers of suicidal ideation during citalopram treatment of major depression. Am. J. Psychiatry 164(10), 1530-1538 (2007). (Pubitemid 350069732)
30. Perlis RH, Purcell S, Fava M et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch. Gen. Psychiatry 64(6), 689-697 (2007). (Pubitemid 46878669)
31. Menke A, Lucae S, Kloiber S et al. Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am. J. Psychiatry 165(7), 917-918 (2008). (Pubitemid 351948730)
32. Laje G, Allen AS, Akula N, Manji H, Rush A John, McMahon FJ. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet. Genomics 19(9), 666-667 (2009).
33. Perroud N, Aitchison KJ, Uher R et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34(12), 2517-2528 (2009).
34. Brent D, Melhem N, Turecki G. Pharmacogenomics of suicidal events. Pharmacogenomics 11(6), 793-807 (2010).
35. Lucire Y, Crotty C. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmgenomics Pers. Med. 4, 65-81 (2011).
36. Perroud N, Uher R, Ng MY et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. 12(1), 68-77 (2012).
37. Menke A, Domschke K, Czamara D et al. Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology 37(3), 797-807 (2012).
38. Brent D, Melhem N, Ferrell R. Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study. Am. J. Psychiatry 167(2), 190-197 (2010).